Thenergo NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Theradiag SA Receives 3rd CE Mark Approval for New Anti-CCP In-Vitro Diagnostic Kit in Rheumatoid Arthritis
Theradiag SA announced that it has obtained a CE mark for its anti-CCP in vitro diagnostic (IVD) kit in rheumatoid arthritis.
Latest Key Developments in Biotechnology
- BioSpecifics Technologies Corp announces FDA approval of XIAFLEX for treatment of peyronie's disease
- Xencor Inc announces closing of initial public offering
- Genmab reaches milestone from Janssen and raises FY 2013 financial guidance
- Genmab says milestone from Lundbeck puts revenue at top end of FY 2013 outlook range
- Share this
- Digg this